Affiliation:
1. From the Cancer DivisionMedical Research Council Clinical Trials Unit, London, and Christie and Wythenshawe Hospital National Health Service Trusts, Manchester, United Kingdom.
Abstract
PURPOSE: The treatment of small-cell lung cancer patients with good performance status aims to improve survival. Dose-intensification could be a way to achieve improved survival but can be limited by neutropenia and thrombocytopenia. Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rhône-Poulenc, Tokyo, Japan) support. The present multicenter randomized trial was designed to examine whether such dose-intensification improves survival while maintaining acceptable toxicity levels. PATIENTS AND METHODS: All patients were randomized to receive six cycles of ACE either every 3 weeks (control [C] group) or every 2 weeks with G-CSF (G group). The standard dose-intensity of ACE was increased by 50% in group G. RESULTS: Four hundred and three patients (G group: n = 201; C group: n = 202) were randomized. The received dose-intensity was 34% higher in the G group than in the C group. Complete response rates were 40% for the G group and 28% for the C group (P = .02), and overall rates were 78% for the G group and 79% for the C group. Survival was longer in the G group (hazard ratio = 0.80; 95% confidence interval, 0.65 to 0.99; P = .04), survival rates for the G and C groups being 47% and 39% at 12 months and 13% and 8% at 24 months, respectively. Metastasis-free survival, nonhematologic toxicity, and quality of life were similar in the two groups. In the G group, there was less neutropenia but more thrombocytopenia and more frequent blood and platelet transfusions. CONCLUSION: Increasing the dose-intensity of ACE with G-CSF support improved survival while maintaining acceptable toxicity.
Publisher
American Society of Clinical Oncology (ASCO)
Reference23 articles.
1. Aisner L, Whitacre M, Van Echo DA, et al: Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother Pharmacol 7:187,1982-193,
2. Bunn PA, Greco FA, Einhorn L: Cyclophosphamide, doxorubicin and etoposide as first-line therapy in the treatment of small cell lung cancer. Semin Oncol 13:45,1986-53, (suppl 3)
3. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 315:164,1991-170,
4. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
5. The importance of dose intensity in chemotherapy of metastatic breast cancer.
Cited by
204 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献